Condition: Craniopharyngiomas · Sponsor: Nanfang Hospital, Southern Medical University
Primary Aim: To assess the objective remission rate (ORR) of patients with recurrent craniopharyngiomas treated with anlotinib . Secondary Aims: 1. To assess progression-free survival (PFS) and overall survival (OS) of patients with recurrent craniopharyngiomas treated with anlotinib. 2. To analyze the disease control rate (DCR) of the anlotinib treatment regimen in patients with recurrent craniopharyngiomas, including the proportion of patients in complete remission, partial remission and stable disease. 3. Monitor and evaluate the safety of anlotinib, especially the occurrence of drug-related adverse events (AEs) .
This description comes directly from the study's public registry record.
Jun Pan, MD, Ph.D · +86-13076878155 · 1448875873@qq.com
Yilamujiang Ainiwan, MD, Ph.D · +86-18620263425 · 1531506809@qq.com
Always discuss trial participation with your own doctor first.
| Southern Medical University, Nanfang Hospital, Department of Neurosurgery | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06970145